跳過主要內容
Quest Diagnostics Home

當患者返回預防保健時,我們可以為您提供支持

While every health system has its own approach to handling the return to preventive and elective patient care during the COVID-19 pandemic, rest assured we are prepared to continue to support your organization, physicians, and patients in whatever capacity you may need.

\r\n","@type":"corporate/components/text"}}" id="text-1238ff1cc2" class="cmp-text">

盡管每個衛生係統都有自己的方法來處理COVID-19大流行期間的預防和選擇性患者護理的回報,但請放心,我們準備繼續以您可能需要的任何身份支持您的組織,醫生和患者。

幫助您管理過渡到後大規模護理診斷

為Covid-19創建的新醫療保健需求做好準備

The COVID-19 pandemic has resulted in a 46% decline in identifying new cancer diagnoses in the US, causing delayed delivery of treatment. Urgent action is needed to avoid a potential increase in cancer deaths due to delayed diagnoses.1

\r\n","@type":"corporate/components/text"}}" id="text-43bae562d2" class="cmp-text">

COVID-19的大流行導致美國識別新癌症診斷的46%下降,導致治療的分娩延遲。需要緊急行動以避免由於診斷延遲而導致的癌症死亡的潛在增加。1

According to provisional data, in 2020, there were notable changes in the number and ranking of deaths compared with 2019. Heart disease-related deaths increased by 4.8%, the largest increase in heart disease deaths since 2012. Increases in heart disease, Alzheimer's disease, and diabetes also reflect disruptions in healthcare that hampered early detection and disease management.2

\r\n","@type":"corporate/components/text"}}" id="text-cda38a1825" class="cmp-text">

根據臨時數據,與2019年相比,2020年的死亡人數和排名發生了顯著變化。與心髒病相關的死亡增加了4.8%,這是自2012年以來心髒病死亡的最大增長。心髒病增加。,糖尿病還反映了醫療保健中的破壞,從而阻礙了早期發現和疾病管理。2

Clinical drug testing decreased up to 70% during the pandemic, while positivity for nonprescribed drugs and dangerous drugs in combination nearly doubled. These trends indicate an unmet need for healthcare and public health resources that address the convergence of the drug epidemic and COVID-19 pandemic.3

\r\n","@type":"corporate/components/text"}}" id="text-cde358af51" class="cmp-text">

在大流行期間,臨床藥物測試最多降低了70%,而對非處方藥和危險藥物的陽性組合幾乎翻了一番。這些趨勢表明,對醫療保健和公共衛生資源的需求未滿足,以解決藥物流行和Covid-19大流行的融合。3

There is a growing body of evidence of a high prevalence of blood clots, strokes, heart attacks, and organ failure among patients infected with SARS-CoV-2 (COVID-19).4

\r\n","@type":"corporate/components/text"}}" id="text-f749b34d63" class="cmp-text">

感染SARS-COV-2的患者(COVID-19)患者的血凝塊,中風,心髒病發作和器官衰竭的流行率越來越大(COVID-19)。4

The number of positive Hepatitis C (HCV) RNA diagnostic test results and medication prescriptions were 40% lower than the previous year, according to an early pandemic study. This was attributed to patients not accessing healthcare services for potentially life-saving treatment and care during the early months of the pandemic.5

\r\n","@type":"corporate/components/text"}}" id="text-63cfa40e5e" class="cmp-text">

根據早期大流行研究,乙型肝炎(HCV)RNA診斷測試結果和藥物處方的陽性診斷測試結果和藥物處方的數量低40%。這歸因於患者在大流行的早期幾個月中未獲得醫療服務的潛在挽救生命治療和護理。5

At least 1 in 7 patients with COVID-19 were found to be additionally infected with a secondary bacterial infection. Of the fatalities during the SARS-CoV-2 epidemic, 50% were caused by untreated or untreatable secondary bacterial infections, in most cases in the lung.6

\r\n","@type":"corporate/components/text"}}" id="text-8ed1abeb5a" class="cmp-text">

發現共vid-19中至少有1例被發現還感染了繼發性細菌感染。在SARS-COV-2流行期間的死亡人數中,有50%是由未經治療或不可治療的繼發性細菌感染引起的,在肺中的大多數情況下。6

1 in 3 patients with COVID-19 were diagnosed with a neurological or psychiatric disorder within 6 months of infection. A study of over 230,000 patients shows the potential detriment to brain health following a COVID-19 diagnosis.7

\r\n","@type":"corporate/components/text"}}" id="text-3187b52973" class="cmp-text">

在感染6個月內,有3例COVID-19患者中有1例被診斷出患有神經或精神疾病。一項對23萬名患者的研究表明,在COVID-19診斷後,對大腦健康的潛在損害。7

現在是時候確保您的實驗室盡可能高效

Quest can provide insights that help lab managers, pathologists, and clinicians collaborate to drive targeted enhancements in test selection and interpretation, and improvements in lab operations and patient outcomes.

\r\n

Our experts can review your lab operations and help implement changes to increase lab efficiency and productivity, helping you manage post-COVID test volumes. Opportunities for efficiency include increasing process standardization, moving high-cost testing off-site, balancing staffing with volume and workflow, and more.

\r\n","@type":"corporate/components/text"}}" id="text-9db598c183" class="cmp-text">

Quest可以提供見解,以幫助實驗室經理,病理學家和臨床醫生合作,以推動針對測試選擇和解釋的有針對性增強,並改善實驗室操作和患者結果。

我們的專家可以審查您的實驗室操作,並幫助實施更改以提高實驗室效率和生產力,從而幫助您管理後循環後的測試量。效率的機會包括提高流程標準化,將高成本測試的現場測試,平衡人員配備與數量和工作流程等等。

延遲的HCV檢測和治療可能導致發病率和死亡率增加

新研究表明,2020年7月的HCV RNA診斷測試結果和藥物處方的陽性數量下降了40%,相比2018/2019同期,這是由於患者無法獲得醫療服務,以便在早期獲得潛在的挽救生命治療和護理的醫療服務大流行的月份。

查看摘要

COVID-19測試

A molecular test is available to test symptomatic patients for COVID-19. Through qualitative multi-target molecular diagnostics, this testing option helps to detect the presence of SARS-CoV-2.

\r\n","@type":"corporate/components/text"}}" id="text-af2c190231" class="cmp-text">

一個分子測試可用於測試Covid-19的有症狀患者。通過定性多目標分子診斷,這種測試選項有助於檢測SARS-COV-2的存在。

Cotesting options can help differentially detect or evaluate the pathogen(s) responsible for a patient’s respiratory infection. These cotesting options include many clinical advantages including, but not limited to, collecting a single specimen, potentially minimizing patient discomfort and expediting time to diagnosis.

\r\n\r\n","@type":"corporate/components/text"}}" id="text-a305b33bff" class="cmp-text">

固定選擇可以幫助差異地檢測或評估導致患者呼吸道感染的病原體。這些選擇的選擇包括許多臨床優勢,包括但不限於收集單個標本,可能最大程度地減少患者不適感和加快診斷時間。

The following testing options can help identify recent or prior infection with SARS-CoV-2 (which may be resolved or is still resolving):

\r\n\r\n","@type":"corporate/components/text"}}" id="text-85fe9482b1" class="cmp-text">

以下測試選項可以幫助識別SARS-COV-2的近期或事先感染(可以解決或仍在解決):

1Kaufman HW,Chen Z,Niles J等。在2019年冠狀病毒疾病(COVID-19)大流行之前和期間,美國新鑒定的癌症患者人數的變化。JAMA NetW Open。2020; 3(8):E2017267。doi:10.1001/jamanetworkopen.2020.172677

2艾哈邁德FB,安德森RN。2020年美國死亡的主要原因。賈馬。2021; 325(18):1829-1830。doi:10.1001/jama.2021.5469

3Niles JK,Gudin J,Radcliff J,Kaufman HW。COVID-19大流行中的阿片類藥物流行:2020年的藥物測試。Popul Health Manag。2021; 24(S1):S43-S51。

4Varga Z,Flammer AJ,Steiger P等。COVID-19中的內皮細胞感染和內皮炎。柳葉刀。2020; 395(10234):1417-1418。doi:10.1016/s0140-6736(20)30937-5

5Kaufman HW,Bull-Otterson L,Meyer III WA等。在19009年大流行期間,丙型肝炎測試和治療的減少。Am J Prev Med。EPUB,2021年5月10日。2021年8月6日訪問。DOI:10.1016/j.amepre.2021.03.011

6Manohar P,Loh B,Athira S等。肺部病毒疾病期間的次要細菌感染:噬菌體治療劑作為抗生素的替代品?前微生物。2020; 11:1434。doi:10.3389/fmicb.2020.01434

7Taquet M,Geddes JR,Husain M等。在236,379名Covid-19的幸存者中,有6個月的神經和精神病結局:使用電子健康記錄的回顧性隊列研究。柳葉刀精神病學。2021; 8(5):416-427。doi:10.1016/s2215-0366(21)00084-5

•Cepheid SARS-COV-2,流感A/B和RSV測試,COBAS®SARS-COV-2和流感A/B測試以及Quest SARS-COV-2 RT-PCR測試和其他分子測試(“測試)”)尚未被FDA清除或批準。

•ROCHE®檢驗僅授權從SARS-COV-2病毒,流感A病毒和流感B病毒中檢測RNA,而沒有任何其他病毒或病原體。

•Cepheid SARS-COV-2,流感A/B和RSV檢驗僅用於同時從SARS-COV-2,流感,流感B和呼吸道合成病毒(RSV)的核酸同時檢測和分化的核酸分化和分化,而不是其他任何病毒或病原體;

•CepheID SARS-COV-2,流感A/B和RSV測試僅在聲明的持續時間內獲得授權,即存在情況,證明授權緊急使用體外診斷,以檢測和/OR診斷,以檢測和/OR診斷。《聯邦食品,毒品和化妝品法》第564(b)(1)條,美國法典21。§360BBB-3(b)(1),除非授權更早終止或吊銷。

•Roche檢驗僅在聲明的持續時間內被授權,即存在情況,證明了授權在第564條根據SARS-COV-2病毒,流感和流感B的檢測和分化的體外診斷授權授權。)(1)法案,美國法典第21卷。§360BBB-3(b)(1),除非授權早日終止或吊銷。

•該測試已由FDA根據EUA授權,供實驗室使用,該實驗室經1988年的臨床實驗室改進修正案(CLIA),美國法典42,美國法典。§263a,進行中等和高複雜性測試。

•QUEST測試和其他分子測試僅授權用於從SARS-COV-2檢測核酸,而不是用於任何其他病毒或病原體。

•QUEST測試和其他分子測試僅在聲明的持續時間內授權,即存在情況,證明了授權在第564(b)(1)條根據第564(b)(1)條根據COVID-19進行緊急使用的授權。該法案,美國法典21§360BBB-3(b)(1),除非授權更早終止或吊銷。

支持您的係統

當您努力跟上持續的Covid-19護理時,趕上延期護理會給臨床人員帶來進一步的壓力。

看看我們如何提供幫助
Baidu
map